A phase 2 trial finds that litifilimab, a monoclonal antibody targeting plasmacytoid dendritic cells, significantly outperformed placebo in clearing skin lesions in patients with moderate-to-severe cutaneous lupus erythematosus (CLE). At week 16, nearly 15% of treated patients achieved clear or almost clear skin versus just 3% on placebo. The drug was generally well tolerated with no new safety signals.
A phase 2 trial (AMETHYST Part A) has found that litifilimab — a monoclonal antibody that targets plasmacytoid dendritic cells — significantly improved skin disease activity in patients with moderate-to-severe cutaneous lupus erythematosus (CLE) who had failed or couldn't tolerate antimalarial treatments. The randomized, double-blind, placebo-controlled study enrolled 93 adults across Latin America, North America, Asia Pacific, and Europe between 2022 and 2024.
Patients received subcutaneous litifilimab 225 mg or placebo every 4 weeks for 24 weeks alongside standard therapy. Results were encouraging: at week 16, nearly five times more litifilimab-treated patients achieved clear or almost clear skin compared to placebo. By week 24, disease activity scores continued to improve across multiple measures, and the drug was generally well tolerated with no treatment-related serious or fatal adverse events.
Why it matters: CLE is a chronic, disfiguring autoimmune skin condition with limited treatment options — especially for patients who don't respond to antimalarials. Litifilimab's targeted mechanism and early efficacy signal offer a potentially meaningful new option, though larger phase 3 trials will be needed to confirm these findings.
